SG11202104120VA - Multivalent regulatory t cell modulators - Google Patents
Multivalent regulatory t cell modulatorsInfo
- Publication number
- SG11202104120VA SG11202104120VA SG11202104120VA SG11202104120VA SG11202104120VA SG 11202104120V A SG11202104120V A SG 11202104120VA SG 11202104120V A SG11202104120V A SG 11202104120VA SG 11202104120V A SG11202104120V A SG 11202104120VA SG 11202104120V A SG11202104120V A SG 11202104120VA
- Authority
- SG
- Singapore
- Prior art keywords
- multivalent
- regulatory
- cell modulators
- modulators
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862753397P | 2018-10-31 | 2018-10-31 | |
PCT/US2019/058854 WO2020092554A1 (en) | 2018-10-31 | 2019-10-30 | Multivalent regulatory t cell modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104120VA true SG11202104120VA (en) | 2021-05-28 |
Family
ID=70464133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104120VA SG11202104120VA (en) | 2018-10-31 | 2019-10-30 | Multivalent regulatory t cell modulators |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210403579A1 (ja) |
EP (1) | EP3873923A4 (ja) |
JP (1) | JP2022513406A (ja) |
KR (1) | KR20210084587A (ja) |
CN (1) | CN113286814A (ja) |
AU (1) | AU2019369498A1 (ja) |
BR (1) | BR112021008355A2 (ja) |
CA (1) | CA3117529A1 (ja) |
EA (1) | EA202191176A1 (ja) |
IL (1) | IL282502A (ja) |
MX (1) | MX2021005008A (ja) |
SG (1) | SG11202104120VA (ja) |
WO (1) | WO2020092554A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
CA2993009A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
CN111465693A (zh) | 2017-09-28 | 2020-07-28 | 依姆派特生物有限公司 | 用于制备抑制性嵌合抗原受体(iCAR)的通用平台 |
ES2946343T3 (es) * | 2018-03-23 | 2023-07-17 | Lilly Co Eli | Anticuerpos anti-CD137 para combinación con anticuerpos anti-PD-L1 |
CA3164731A1 (en) * | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
EP4136254A4 (en) * | 2020-04-13 | 2024-05-22 | Maddon Advisors LLC | COMPOSITIONS TARGETING ACE2 AND METHODS OF TREATING COVID-19 |
JP2023533514A (ja) * | 2020-06-29 | 2023-08-03 | アリネール・セラピューティクス・リミテッド・ライアビリティ・カンパニー | ヒト化抗emapii治療抗体 |
EP4178359A2 (en) * | 2020-07-07 | 2023-05-17 | Research Institute at Nationwide Children's Hospital | Combination therapies for the treatment and prevention of biofilms |
US20240016839A1 (en) * | 2020-09-04 | 2024-01-18 | ImmPACT Bio USA Inc. | Bicistronic inhibitory chimeric antigen receptor (icar)/activating chimeric antigen receptor (acar) constructs for use in cancer therapies |
EP4320242A1 (en) * | 2021-04-08 | 2024-02-14 | Sana Biotechnology, Inc. | Cd8-specific antibody constructs and compositions thereof |
AR125753A1 (es) * | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos |
CN115989244A (zh) * | 2021-08-06 | 2023-04-18 | 上海驯鹿生物技术有限公司 | Cd5和cd7双靶点的全人源嵌合抗原受体(car)及其应用 |
CA3238769A1 (en) * | 2021-11-23 | 2023-06-01 | William Brondyk | Anti-ngf antibodies and uses thereof |
WO2023225626A2 (en) * | 2022-05-20 | 2023-11-23 | Adanate, Inc. | Multi-targeting lilrb antibodies and uses thereof |
WO2024081602A2 (en) * | 2022-10-11 | 2024-04-18 | Maddon Advisors Llc | Ace2-targeted compositions and methods for treating co0vid-19 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7399847B1 (en) * | 1996-11-25 | 2008-07-15 | The General Hospital Corporation | Nucleic acids encoding artificial P-selectin ligands |
US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
WO2011127412A2 (en) * | 2010-04-09 | 2011-10-13 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
EP2596114A4 (en) * | 2010-07-14 | 2014-01-08 | Amgen Inc | IMMUNOGLOBULIN WITH DOMAIN INSERTION |
CN105734678B (zh) * | 2010-07-16 | 2019-11-05 | 阿迪马布有限责任公司 | 合成多核苷酸文库 |
US9212227B2 (en) * | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
UY34813A (es) * | 2012-05-18 | 2013-11-29 | Amgen Inc | Proteínas de unión a antígeno dirigidas contra el receptor st2 |
US9631191B2 (en) * | 2012-12-04 | 2017-04-25 | Alexey Gennadievich Zdanovsky | System for production of antibodies and their derivatives |
MX2017012352A (es) * | 2015-04-03 | 2018-01-26 | Eureka Therapeutics Inc | Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos. |
US20170204154A1 (en) * | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
CA3044416A1 (en) * | 2016-12-13 | 2018-06-21 | Delinia, Inc. | Multivalent regulatory t cell modulators |
-
2019
- 2019-10-30 CN CN201980080129.9A patent/CN113286814A/zh active Pending
- 2019-10-30 WO PCT/US2019/058854 patent/WO2020092554A1/en unknown
- 2019-10-30 MX MX2021005008A patent/MX2021005008A/es unknown
- 2019-10-30 KR KR1020217016412A patent/KR20210084587A/ko unknown
- 2019-10-30 BR BR112021008355-3A patent/BR112021008355A2/pt not_active Application Discontinuation
- 2019-10-30 US US17/290,129 patent/US20210403579A1/en active Pending
- 2019-10-30 JP JP2021548552A patent/JP2022513406A/ja active Pending
- 2019-10-30 AU AU2019369498A patent/AU2019369498A1/en not_active Abandoned
- 2019-10-30 EA EA202191176A patent/EA202191176A1/ru unknown
- 2019-10-30 SG SG11202104120VA patent/SG11202104120VA/en unknown
- 2019-10-30 CA CA3117529A patent/CA3117529A1/en active Pending
- 2019-10-30 EP EP19877795.5A patent/EP3873923A4/en not_active Withdrawn
-
2021
- 2021-04-21 IL IL282502A patent/IL282502A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021005008A (es) | 2021-06-15 |
CA3117529A1 (en) | 2020-05-07 |
EA202191176A1 (ru) | 2021-07-28 |
EP3873923A1 (en) | 2021-09-08 |
JP2022513406A (ja) | 2022-02-07 |
CN113286814A (zh) | 2021-08-20 |
BR112021008355A2 (pt) | 2021-08-03 |
AU2019369498A1 (en) | 2021-05-20 |
KR20210084587A (ko) | 2021-07-07 |
WO2020092554A1 (en) | 2020-05-07 |
IL282502A (en) | 2021-06-30 |
US20210403579A1 (en) | 2021-12-30 |
EP3873923A4 (en) | 2023-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282502A (en) | Multivalent regulatory T cell modulators | |
EP3554525A4 (en) | MULTIVALENT REGULATORS T LYMPHOCYTE MODULATORS | |
PL3743406T3 (pl) | Modulatory tmem16a | |
GB201813178D0 (en) | Cell | |
IL274537A (en) | nuclear receptor modulators | |
GB2596231B (en) | Modulators | |
GB201803079D0 (en) | Cell | |
SG11201800806WA (en) | Optical modulator | |
GB201716468D0 (en) | Modulators | |
GB201704739D0 (en) | Optical modulator | |
IL266261A (en) | ror-gamma modulators | |
GB201819540D0 (en) | T cell modification | |
IL285074A (en) | gpr35 modulators | |
GB201807693D0 (en) | Cell | |
GB2564099B (en) | Electro-Optic Modulator | |
SG11201901323RA (en) | Optical modulator | |
GB2585587B (en) | Modulators | |
GB201816399D0 (en) | Cell | |
GB2563095B (en) | Modulators | |
GB201805918D0 (en) | Cell | |
GB2557694B (en) | Optical modulators | |
GB2589174B (en) | Electro-optic modulator | |
GB2577995B (en) | Cell | |
GB2571429B (en) | Optical modulator | |
GB201820443D0 (en) | Cell |